Clinical trials
Phase 3 Breast Neoplasms trials in Argentina
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
117 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 3 |
| 2002 | 1 |
| 2003 | 5 |
| 2004 | 4 |
| 2006 | 8 |
| 2007 | 3 |
| 2008 | 4 |
| 2009 | 5 |
| 2010 | 6 |
| 2011 | 5 |
| 2012 | 7 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 5 |
| 2020 | 4 |
| 2021 | 8 |
| 2022 | 8 |
| 2023 | 8 |
| 2024 | 4 |
| 2025 | 9 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 64 |
| Active, not recruiting | 26 |
| Recruiting | 15 |
| Terminated | 7 |
| Unknown status | 3 |
| Enrolling by invitation | 1 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hoffmann-La Roche | 24 |
| Novartis Pharmaceuticals | 16 |
| AstraZeneca | 11 |
| Eli Lilly and Company | 8 |
| Pfizer | 8 |
| Sanofi | 5 |
| Merck Sharp & Dohme LLC | 4 |
| Amgen | 3 |
| Bayer | 3 |
| GlaxoSmithKline | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Breast Neoplasms | 117 |
| Neoplasm Metastasis | 19 |
| Neoplasms | 8 |
| Triple Negative Breast Neoplasms | 4 |
| Breast Diseases | 2 |
| Breast Neoplasms, Male | 2 |
| Neutropenia | 2 |
| Recurrence | 2 |
| Unilateral Breast Neoplasms | 2 |
| Anemia | 1 |
Trials
Showing 1 to 25 of 117. Each trial links to its page on Pharma Observatory.
17 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.